カテゴリー： DelveInsight, MOA2018, 世界, 医療/バイオ

インターロイキン－2阻害剤のパイプライン・インサイト2018

【英語タイトル】Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2018

DelveInsightが出版した調査資料（DIMR2016404）・商品コード：DIMR2016404
・発行会社（調査会社）：DelveInsight
・発行日：2019年02月
・ページ数：約60
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名使用）USD1,250 ⇒換算￥136,250見積依頼/購入/質問フォーム
Site Price（同一国内共有可）USD2,500 ⇒換算￥272,500見積依頼/購入/質問フォーム
Enterprise Price（複数国内共有可）USD4,000 ⇒換算￥436,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査レポートでは、世界におけるインターロイキン－2阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・インターロイキン－2阻害剤の概要
・インターロイキン－2阻害剤のパイプライン概要
・企業別開発中のインターロイキン－2阻害剤
・後期治験段階の薬剤(Filed & Phase III)：比較分析
・中期治験段階の薬剤(Phase II)：比較分析
・初期治験段階の薬剤(Phase I & IND Filed)：比較分析
・薬剤候補のプロファイル
・インターロイキン－2阻害剤の評価
　　- 単剤治療薬別評価
　　- 併用治療薬別評価
　　- 投与経路別評価
　　- 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・インターロイキン－2阻害剤開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Interleukin-2 (IL-2) Inhibitors-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Interleukin-2 (IL-2) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Interleukin-2 (IL-2) Inhibitors. DelveInsight’s Report also assesses the Interleukin-2 (IL-2) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Interleukin-2 (IL-2) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Interleukin-2 (IL-2) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Interleukin-2 (IL-2) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Interleukin-2 (IL-2) Inhibitors Overview
• Interleukin-2 (IL-2) Inhibitors Disease Associated
• Interleukin-2 (IL-2) Inhibitors Pipeline Therapeutics
• Interleukin-2 (IL-2) Inhibitors Therapeutics under Development by Companies
• Interleukin-2 (IL-2) Inhibitors Filed and Phase III Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Phase II Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Interleukin-2 (IL-2) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors – Discontinued Products
• Interleukin-2 (IL-2) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Interleukin-2 (IL-2) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors by Therapy Area, 2018
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Interleukin-2 (IL-2) Inhibitors Assessment by Monotherapy Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Combination Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Molecule Type
• Interleukin-2 (IL-2) Inhibitors Therapeutics – Discontinued Products
• Interleukin-2 (IL-2) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors by Therapy Area, 2018
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Interleukin-2 (IL-2) Inhibitors Assessment by Monotherapy Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Combination Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

インターロイキン－2阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[インターロイキン－2阻害剤のパイプライン・インサイト2018] (コード：DIMR2016404)販売に関する免責事項を必ずご確認ください。
★調査レポート[インターロイキン－2阻害剤のパイプライン・インサイト2018]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • FGFR4阻害剤：パイプラインインサイト2018
    DELV201939 / DelveInsight / 2018年1月 / 本調査レポートでは、FGFR4阻害剤の治療薬開発パイプラインについて調査・分析し、FGFR4阻害剤の概要、FGFR4阻害剤の臨床試験段階の治療薬分析、主要な製薬メーカー動向などを含め、以下の構成でお届け致します。 ・FGFR4阻害剤の概要 ・FGFR4阻害剤の治療薬開発パイプライン ・FGFR4阻害剤の比較分析 ・FGFR4阻害剤の治験段階の製品（医薬品） ・FGFR4阻害剤の前臨床＆創薬段階の製品 ・主要企業動向 ・治療評価（分析） …..."Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insight, 2018 - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insight, 2018 development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages: • Clinical • Non-clinical • Inactive: Discontinued and/or Dormant Descriptive coverage of pipeline development activities...

    • ◆H&Iグローバルリサーチのお客様（例）◆